Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 versus pemetrexed or docetaxel in EGFR-mutant NSCLC after EGFR-TKI progression
NL-OMON39976Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Luminespib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Jan 2013; status: active, not recruiting.
02
Drugs
Luminespib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON39976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39976.